What is PleoPharma?
PleoPharma operates at the intersection of biotechnology and neurology, focusing on the development of novel therapies for complex conditions that currently lack FDA-approved interventions. The company has distinguished itself through a robust research pipeline, most notably with a lead program that has successfully navigated Phase 2 clinical trials. By fostering strategic collaborations with healthcare providers and academic researchers, PleoPharma is positioning itself as a leader in addressing unmet medical needs, aiming to alleviate the widespread suffering associated with chronic neurological and substance-related disorders.
How much funding has PleoPharma raised?
PleoPharma has raised a total of $42.1M across 2 funding rounds:
Private Equity
$6.2M
Series B
$36M
Private Equity (2025): $6.2M, investors not publicly disclosed
Series B (2025): $36M, investors not publicly disclosed
Key Investors in PleoPharma
Undisclosed Investor
An institutional capital partner specializing in late-stage biotech growth and pharmaceutical infrastructure development.
Undisclosed Investor
A strategic investment firm focused on high-impact medical research and the commercialization of novel CNS therapies.
Undisclosed Investor
A specialized syndicate providing essential backing for companies addressing critical unmet needs in substance abuse and neurology.
What's next for PleoPharma?
With the recent strategic investment, PleoPharma is well-positioned to accelerate its clinical roadmap and scale its operational capabilities. The company is expected to prioritize the advancement of its lead program toward late-stage trials, a critical milestone for regulatory approval. Furthermore, the influx of capital will likely support the expansion of its research infrastructure and the strengthening of its collaborative network, ensuring that the firm remains at the forefront of medical innovation. As the company moves forward, the focus will remain on translating scientific breakthroughs into tangible patient outcomes, thereby solidifying its market position in the competitive pharmaceutical sector.
See full PleoPharma company page
